13Jul 2024
Eftilagimod Alpha and Pembrolizumab in HNSCC: TACTI-003 Results

Eftilagimod Alpha and Pembrolizumab in HNSCC: TACTI-003 Results

The study examines eftilagimod alpha (E) and pembrolizumab (P) in first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with CPS <1. Eftilagimod alpha, a soluble LAG-3 protein, activates antigen-presenting cells and recruits T-cells. Previous phase II results showed promising response rates. This primary analysis focuses on PD-L1 CPS-negative patients, aiming to evaluate the efficacy and potential of this combination therapy.

  • #oncology

Like

Save

Share